Lexicon Pharmaceuticals Inc. LXRX) on Tuesday reported a loss of $64.8 million in its third quarter. On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 18 cents.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an ...

Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance, making market penetration difficult. Inpefa’s early commercial results are underwhelming ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) lost ~39% in the morning hours on Friday following a trading halt in the previous session as an FDA advisory committee declined to endorse its diabetes ...

THE WOODLANDS, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has closed screening and expects to complete enrollment ahead of ...

“We’ve also been asking for guidance on just to kind of basic lexicon and glossary of terminology that would ... In the ...

During the last three months, 8 analysts shared their evaluations of Lexicon Pharmaceuticals LXRX, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...

In the last three months, 7 analysts have published ratings on Lexicon Pharmaceuticals LXRX, offering a diverse range of perspectives from bullish to bearish. The following table provides a quick ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), retaining the price target of $10.00. Joseph Pantginis has given his Buy ...

In this Lexicon, authored by an international team of scholars, over 200 entries define and explain the key concepts, categories, philosophemes, themes, debates, and names associated with the entire ...

Whether you’re a golf fan or a pro, there can be quite a few terms thrown out on the green. FOX 16’s Kevin Kelly breaks down ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...